Anti-atopic cream

An anti-allergic and cream technology, applied in aerosol delivery, medical preparations with inactive ingredients, plant raw materials, etc., can solve problems such as insufficient inhibition and unsuitability for long-term use.

Inactive Publication Date: 2015-06-24
NJY LIFE ENG
View PDF3 Cites 7 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0008] Antihistamine therapy was shown to be insufficient to suppress itching in patients with atopic dermatitis, and steroid use was not suitable for long-term use due to common side effects of steroids (see Jiang et al., 2009; Yun et al., 2008; Koblenzer, 1999; Mihara et al., 2004)

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Anti-atopic cream
  • Anti-atopic cream
  • Anti-atopic cream

Examples

Experimental program
Comparison scheme
Effect test

Embodiment Construction

[0023] summary

[0024] In order to examine the therapeutic effect of the hypoallergenic cream provided by NJY Life Science Co., Ltd on atopic dermatitis, this study was conducted in mice with DNCB-induced BALB / c atopic dermatitis to examine the hypoallergenic efficacy.

[0025] 20 BALB / c mice were divided into each group one by one and randomly assigned to the atopic dermatitis induction control group and the antiallergic cream treatment group.

[0026] When the hypoallergenic cream was applied twice daily for 6 days to mice with severe allergic dermatitis, it has been observed that the skin returned to a normal state, with a clean and smooth surface, without stratum corneum. Moreover, compared with the DNCB-induced allergic control group, the levels of immunoglobulin E and histamine in the blood of the hypoallergenic cream treatment group were significantly reduced by 57.80% and 59.41% dml, respectively (p<0.05). It has also been verified that mice treated with a hypoallerg...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

PUM

No PUM Login to view more

Abstract

The present invention relates to an anti-atopic cream comprising: a first component comprising Houttuynia cordata, Acori gramineri Rhizoma, Saposhnikoviae Radix, Astragalus membranaceus Radix, Eriobotryae Folium, Sophorae flavescentis Radix, Saururus chinensis, Phellodendron bark, Centella asiatica, Arisaematis Rhizoma and Aster yomena; and a second component comprising glycerol, a caprylic or capric triglyceride, sunflower seed oil, butylene glycol, butylene glycol dicaprylate or dicaprate, macadamia seed oil, polyglyceryl-3 methylglucose distearate, PEG-4 olivate, meadowfoam seed oil, dimethicone, cetyl ethylhexanoate, oxidized corn oil, cetearyl alcohol, tocopheryl acetate, glyceryl acrylate or acrylic acid copolymer, stearyl glycyrrhetinate, sodium chloride, sodium acrylate or sodium acryloyl dimethyl taurate copolymer, algin, isohexadecane, caprylyl glycol, polysorbate 80, allantoin, caprylhydroxamic acid, propylene glycol, disodium EDTA and ceramide 3 and, in the anti-atopic cream, the first component and the second component are mixed in a weight ratio of between 5:5 and 7:3. According to the present invention, when the anti-atopic cream is applied to a DNCB induced atopic dermatitis mouse, the blood IgE is reduced and at the same time the amount of discharged histamine produced from the mast cells is suppressed, thereby making it possible to provide an anti-atopic cream having a therapeutic effect in atopic dermatitis.

Description

technical field [0001] The present invention relates to a hypoallergenic cream which, when applied to mice with DNCB-induced atopic dermatitis, reduces blood immunoglobulin E levels while inhibiting the production of histamine by mast cells amount, thus having a therapeutic effect on atopic dermatitis. Background technique [0002] The present invention relates to a hypoallergenic cream which, when applied to mice with DNCB-induced atopic dermatitis, reduces the level of blood immunoglobulin E while inhibiting the amount of released histamine produced by mast cells , which has a therapeutic effect on allergic dermatitis. [0003] Recently, the number of infants and adolescent patients suffering from atopic dermatitis has rapidly increased in Korea. [0004] According to the 2008 Public Health and Nutrition Study, 19.2% of children between the ages of 1 and 5 years (ie about one in five children) suffer from atopic dermatitis (NHNS, 2009). [0005] Atopic dermatitis is a c...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to view more

Application Information

Patent Timeline
no application Login to view more
Patent Type & Authority Applications(China)
IPC IPC(8): A61K9/06A61K36/78A61K36/882A61K36/23
CPCA61K9/0014A61K9/06A61K36/185A61K36/23A61K36/238A61K36/28A61K36/481A61K36/489A61K36/73A61K36/756A61K36/78A61K36/882A61K36/8884A61K36/899A61K47/10A61K47/14A61K47/44A61K2300/00
Inventor 卢佳永卢宰永
Owner NJY LIFE ENG
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Try Eureka
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap